Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling.
Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling.
复制标题
DOI：
10.1186/1477-5956-7-34
复制
发表时间：
2009-09-03
期刊：
影响因子：
2
通讯作者：
Jimenez CR
中科院分区：
文献类型：
--
作者：
Voortman J;Pham TV;Knol JC;Giaccone G;Jimenez CR
只有少数晚期非小细胞肺癌（NSCLC）患者从化疗中获益。对NSCLC患者进行血清肽谱分析，以研究与治疗结果相关的模式。采用磁珠辅助血清肽捕获结合基质辅助激光解吸电离飞行时间质谱（MALDI-TOF-MS）技术，获得了27例接受顺铂-吉西他滨化疗和硼替佐米治疗的NSCLC患者的血清肽质量谱。基于治疗前肽谱的差异和治疗期间肽丰度的动态变化，建立了基于支持向量机的预测临床结果的算法。6肽离子特征以82%的准确性、灵敏度和特异性区分治疗后相对较短与较长无进展生存期（PFS）的患者。预测PFS较长与总生存期较长相关。在治疗期间包含显示丰度差异变化的7种肽离子导致13种肽离子特征，在100%灵敏度和73%特异性下具有86%的准确度。5-肽离子特征可以在100%灵敏度和83%特异性下以89%的准确度将具有部分应答的患者与无应答者区分开。当比较NSCLC血清谱与来自无癌症对照受试者的血清谱时，也发现了差异肽谱。这项研究表明，血清肽组分析使用MALDI-TOF-MS结合模式诊断可能有助于预测晚期NSCLC患者化疗的治疗结果。
Only a minority of patients with advanced non-small cell lung cancer (NSCLC) benefit from chemotherapy. Serum peptide profiling of NSCLC patients was performed to investigate patterns associated with treatment outcome. Using magnetic bead-assisted serum peptide capture coupled to matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), serum peptide mass profiles of 27 NSCLC patients treated with cisplatin-gemcitabine chemotherapy and bortezomib were obtained. Support vector machine-based algorithms to predict clinical outcome were established based on differential pre-treatment peptide profiles and dynamic changes in peptide abundance during treatment. A 6-peptide ion signature distinguished with 82% accuracy, sensitivity and specificity patients with a relatively short vs. long progression-free survival (PFS) upon treatment. Prediction of long PFS was associated with longer overall survival. Inclusion of 7 peptide ions showing differential changes in abundance during treatment led to a 13-peptide ion signature with 86% accuracy at 100% sensitivity and 73% specificity. A 5-peptide ion signature could separate patients with a partial response vs. non-responders with 89% accuracy at 100% sensitivity and 83% specificity. Differential peptide profiles were also found when comparing the NSCLC serum profiles to those from cancer-free control subjects. This study shows that serum peptidome profiling using MALDI-TOF-MS coupled to pattern diagnostics may aid in prediction of treatment outcome of advanced NSCLC patients treated with chemotherapy.
登录
查看更多内容
影响因子：
6.2
作者：
Ludwig, H;Khayat, D;Facon, T
通讯作者：
Facon, T
影响因子：
9
作者：
Smith, Fraser M.;Gallagher, William M.;Reynolds, John V.
通讯作者：
Reynolds, John V.
DOI：
10.1093/jnci/djk195
发表时间：
2007-06-06
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Taguchi, Fumiko;Solomon, Benjamin;Carbone, David P.
通讯作者：
Carbone, David P.
DOI：
10.1093/jnci/92.3.205
发表时间：
2000-02-02
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Therasse, P;Arbuck, SG;Gwyther, SG
通讯作者：
Gwyther, SG
影响因子：
2
作者：
Jimenez, Connie R.;El Filali, Zineb;Li, Ka Wan
通讯作者：
Li, Ka Wan